Other Income & Expense
Other Income (Expense)
Kailera Therapeutics Other Income (Expense) increased by 134.1% to $5.80M in Q1 2026 compared to the prior quarter.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
An increase suggests higher non-operating gains or lower non-operating costs, while a decrease indicates higher non-operating expenses or lower non-operating income.
Detailed definition
Represents the net total of non-operating financial activities, including interest income, interest expense, foreign cur...
Peer comparison
Standard across all public companies; peers in the medical device sector often show similar volatility due to currency fluctuations.
Metric ID:
other_income_expense_netHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $2.48M | $5.80M |
| QoQ Change | — | +134.1% |
| YoY Change | — | +134.1% |
Range$2.48M – $5.80M
Avg YoY Growth+134.1%
Median YoY Growth+134.1%
Other Income (Expense) at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's other income (expense)?
- Kailera Therapeutics (KLRA) reported other income (expense) of $5.80M in Q1 2026.
- What does other income (expense) mean?
- The net result of all income and expenses not related to core business operations.